Market research
NLTX Neoleukin Therapeutics
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- 0.0%
- Beta
- 1.1
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- 0.0%
- Beta
- 1.1
About
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Research context
Neoleukin Therapeutics appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NLTX discussion.
5 years, 7 months ago
Neoleukin Therapeutics, Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Neoleukin Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 310.8% to $-33M since the same quarter in the previous year.
Finally, its free cash flow fell by 82.4% to $-10M since the same quarter in the previous year.
Based on the above factors, Neoleukin Therapeutics, Inc gets an overall score of 1/5.